Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice

Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice

Parkinson’s disease (PD) is characterized by dopaminergic nigrostriatal neurons degeneration and Lewy body pathology, mainly composed of α-synuclein (αSyn) fibrillary aggregates. We recently described that the neuronal phosphoprotein Synapsin III (Syn III) participates in αSyn pathology in PD brains...

Full description

Bibliographic Details
Main Authors: Andrea Casiraghi, Francesca Longhena, Gaia Faustini, Giovanni Ribaudo, Lorenzo Suigo, Gisela Andrea Camacho-Hernandez, Federica Bono, Viviana Brembati, Amy Hauck Newman, Alessandra Gianoncelli, Valentina Straniero, Arianna Bellucci, Ermanno Valoti
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Pharmaceutics
Subjects:
Parkinson’s disease
α-synuclein/synapsin III complex
methylphenidate analogues
<i>threo</i> methyl 2-(piperidin-2-yl)-2-(p-tolyl)acetate hydrochloride
motor recovery effect
Online Access:https://www.mdpi.com/1999-4923/14/8/1595

Internet

https://www.mdpi.com/1999-4923/14/8/1595

Similar Items